![Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial - The Lancet Global Health Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial - The Lancet Global Health](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ceb6372d-42fe-4f60-8ec5-17f84e1514d8/gr1.gif)
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial - The Lancet Global Health
![Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study - The Lancet Respiratory Medicine Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study - The Lancet Respiratory Medicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1e936b8c-7005-418b-b23d-1ebf0f602d0b/gr1.gif)
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study - The Lancet Respiratory Medicine
![The Lancet Handbook of Essential Concepts in Clinical Research (The Lancet Handbooks): Schulz PhD MBA, Kenneth, Grimes MD, David A.: 9780080448664: Amazon.com: Books The Lancet Handbook of Essential Concepts in Clinical Research (The Lancet Handbooks): Schulz PhD MBA, Kenneth, Grimes MD, David A.: 9780080448664: Amazon.com: Books](https://images-na.ssl-images-amazon.com/images/I/41dYMGNY49L.jpg)
The Lancet Handbook of Essential Concepts in Clinical Research (The Lancet Handbooks): Schulz PhD MBA, Kenneth, Grimes MD, David A.: 9780080448664: Amazon.com: Books
![Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/2969b73f-983d-4453-8f98-f1945d2cffd3/gr1.jpg)
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
![Scabies outbreaks in ten care homes for elderly people: a prospective study of clinical features, epidemiology, and treatment outcomes - The Lancet Infectious Diseases Scabies outbreaks in ten care homes for elderly people: a prospective study of clinical features, epidemiology, and treatment outcomes - The Lancet Infectious Diseases](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/c8dd30c0-1307-402f-b060-d68df364ff21/gr1.jpg)
Scabies outbreaks in ten care homes for elderly people: a prospective study of clinical features, epidemiology, and treatment outcomes - The Lancet Infectious Diseases
![A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial - The Lancet Regional Health – Americas A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial - The Lancet Regional Health – Americas](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/66a16ecc-2abe-4c26-bf97-7666ea85d37b/gr1.jpg)
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial - The Lancet Regional Health – Americas
![Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/d94350f3-51ae-4667-a156-b8ad998055ce/gr1.jpg)
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases
![Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial - The Lancet Respiratory Medicine Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial - The Lancet Respiratory Medicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/0ed07044-02d7-4c0e-95a7-b9a3d949e5df/gr1.jpg)
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial - The Lancet Respiratory Medicine
![Etrolizumab for ulcerative colitis: beyond what meets the eye - The Lancet Gastroenterology & Hepatology Etrolizumab for ulcerative colitis: beyond what meets the eye - The Lancet Gastroenterology & Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/9e849912-9474-4718-9f4a-b49eee429102/gr1.jpg)
Etrolizumab for ulcerative colitis: beyond what meets the eye - The Lancet Gastroenterology & Hepatology
![Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study - The Lancet Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/d892a788-6b3b-4f0e-8bd4-d28f07224a50/gr1.jpg)
Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study - The Lancet
![Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial - The Lancet Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/6a8769bf-4740-4d3f-87da-789c8a005eef/gr1.jpg)
Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial - The Lancet
![Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context - The Lancet Respiratory Medicine Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context - The Lancet Respiratory Medicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/26b25721-0492-4b9e-b34e-960bee70396d/gr1.jpg)
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context - The Lancet Respiratory Medicine
![A clinical prediction rule for ambulation outcomes after traumatic spinal cord injury: a longitudinal cohort study - The Lancet A clinical prediction rule for ambulation outcomes after traumatic spinal cord injury: a longitudinal cohort study - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2001013509/2003814065/gr1.gif)
A clinical prediction rule for ambulation outcomes after traumatic spinal cord injury: a longitudinal cohort study - The Lancet
![Clinical and virological data of the first cases of COVID-19 in Europe: a case series - The Lancet Infectious Diseases Clinical and virological data of the first cases of COVID-19 in Europe: a case series - The Lancet Infectious Diseases](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/0d9449f1-9fe1-43f9-8952-2b532e4a0609/gr1.jpg)
Clinical and virological data of the first cases of COVID-19 in Europe: a case series - The Lancet Infectious Diseases
![Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial - The Lancet Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2065280616/2066305571/gr1.gif)
Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial - The Lancet
![Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review - The Lancet Oncology Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/9d173e22-589c-48cd-a884-6002c1967ffb/gr1.jpg)
Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review - The Lancet Oncology
![Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/e7d31c91-9c6a-4ecc-87eb-2074454af216/gr1a.jpg)
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases
![Linking interdisciplinary and multiscale approaches to improve healthspan—a new UK model for collaborative research networks in ageing biology and clinical translation - The Lancet Healthy Longevity Linking interdisciplinary and multiscale approaches to improve healthspan—a new UK model for collaborative research networks in ageing biology and clinical translation - The Lancet Healthy Longevity](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/979ef28d-a4d7-469a-b358-3363c9a32308/gr1.jpg)
Linking interdisciplinary and multiscale approaches to improve healthspan—a new UK model for collaborative research networks in ageing biology and clinical translation - The Lancet Healthy Longevity
![Prevalence, risk factors, outcomes, and molecular epidemiology of mcr-1-positive Enterobacteriaceae in patients and healthy adults from China: an epidemiological and clinical study - The Lancet Infectious Diseases Prevalence, risk factors, outcomes, and molecular epidemiology of mcr-1-positive Enterobacteriaceae in patients and healthy adults from China: an epidemiological and clinical study - The Lancet Infectious Diseases](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2091598781/2076181218/gr1.gif)